作者投稿
专家审稿
编辑办公
邮件订阅
RSS
-
-
2010年5月11日, 赵玉沛院长、鲁重美书记为北京协和医院特需疑难病会诊中心揭牌。胰腺疾病专家组全体成员、部分职能处室负责人以及近20家媒体记者到场, 共同见证了这一时刻。挂牌仪式结束后, 全体专家前往“特需疑难病会诊中心”所在地, 为首例患者会诊, 媒体记者亦前往现场观摩了此次会诊。
一次挂号, 多个科室的顶级专家会诊, 这是北京协和医院新成立的特需疑难病会诊中心所提供的医疗服务。作为该中心首个挂牌并正式开诊的专病组, 胰腺疾病专家组汇聚了北京协和医院九大品牌科室、20余名顶级专家, 打造了一个国内最高水平的胰腺病诊治平台。这九大科室全部为国家重点学科和重点培育学科, 包括基本外科胰腺组、消化科、内分泌科、肿瘤内科、超声科、病理科、放射科、放疗科、核医学科, 而专家队伍也全部为国内本领域的著名专家。会诊专家团队采取A、B角的模式, 每次会诊各科至少保证1位专家参加。
北京协和医院特需疑难病会诊中心接收的患者主要包括三类:一是已就诊三个专科或在一个专科就诊多次尚未明确诊断者; 二是临床诊断较为明确, 但病情涉及多学科、多系统、多器官, 需要多个专科协同会诊者; 三是已在外院接受手术或其他治疗, 需要进一步确定治疗方案者。
北京协和医院作为卫生部指定的全国疑难重症诊治指导中心, 其优势在于构建了一个多学科、高水平、精尖技术的整体平台。仅以胰腺疾病为例, 基本外科赵玉沛教授牵头的“胰腺癌综合诊治方案的基础研究与临床应用”荣获2008年国家科技进步二等奖, 消化内科陆星华教授牵头的“胰腺癌流行病学、筛查方案及内镜治疗的基础和临床研究”荣获2008年中华医学科技奖二等奖, 在胰腺疾病方面代表了国内最高水平。
赵玉沛院长指出, 建立特需疑难病会诊中心, 是北京协和医院对有效开展跨学科协作诊疗活动所进行的, 可以使患者和医院双赢的组织运作模式的一种探索。对患者来说, 减少了等候时间、提高了诊治质量, 从根本上说是降低了医疗费用; 对医院来说, 可以大大促进各相关学科的发展、带动医生学术水平的整体提高, 促进医院培养全面思维的医学人才等。这样的调整, 也符合我国目前进行的新医改中有关大型公立医院的职责向集中解决疑难重症转化和调整的需要。
(北京协和医院宣传处 陈明雁)
-
[1] Genant HK, Mall JC, Wagonfeld JB, et al. Skeletal demineralization and growth retardation in inflammatory bowel disease [J]. Invest Radiol, 1976, ll:541-549. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=WK_LWW201705250614429
[2] Noble CL, McCullough J, Ho W, et al. Low body mass not vitamin D receptor polymorphisms predict osteoporosis in patients with inflammatory bowel disease[J]. Aliment Pharmacol Ther, 2008, 27 : 588-596. DOI: 10.1111/j.1365-2036.2008.03599.x
[3] Poliak RD, Karmeli F, Eliakim R, et al. Femoral neck osteopenia in patients with inflammatory bowel disease[J]. Am J Gastroenterol, 1998, 93 : 1483-1490. DOI: 10.1111/j.1572-0241.1998.468_q.x
[4] Bjarnason I, Macpherson A, Mackintosh C, et al. Reduced bone density in patients with inflammatory bowel disease[J]. Gut, 1997, 40:228-233. DOI: 10.1136/gut.40.2.228
[5] Card T, West J, Hubbard R, et al. Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study[J]. Gut, 2004, 53:251-255. DOI: 10.1136/gut.2003.026799
[6] Van Staa TP, Leufkens HG, and Cooper C. The epidemiology of corticosteroid-induced osteoporosis : a meta-analysis[J]. Osteoporos Int, 2002, 13:777-787. DOI: 10.1007/s001980200108
[7] Bernstein CN, Leslie WD. The pathophysiology of bone disease in gastrointestinal disease[J]. Eur J Gastroenterol Hepatol, 2003, 15:857-864. DOI: 10.1097/00042737-200308000-00004
[8] Manolagas SC. The role of IL-6 type cytokines and their receptors in bone[J]. Ann N Y Acad Sci, 1998, 840: 194-204. DOI: 10.1111/j.1749-6632.1998.tb09563.x
[9] Schulte CM, Dignass AU, Goebell H, et al. Genetic factors determine extent of bone loss in inflammatory bowel disease [J]. Gastroenterology, 2000, 119:909-920. DOI: 10.1053/gast.2000.18158
[10] Boyce BF, Xing L. The RANKI/RANK/OPG pathway[J]. Curr Osteoporos Rep, 2007, 5:98-104. DOI: 10.1007/s11914-007-0024-y
[11] Bernstein CN, Sargent M, and Leslie WD. Serum osteopro- tegerin is increased in Crohn's disease: a population-based case control study[J]. Inflamm Bowel Dis, 2005, 11: 325-330. DOI: 10.1097/01.MIB.0000164015.60795.ca
[12] Moschen AR, Kaser A, Enrich B, et al. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss[J]. Gut, 2005, 54:479-487. DOI: 10.1136/gut.2004.044370
[13] Hofbauer LC, Lacey DL, Dunstan CR, et al. Interleukin-1 beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells[J]. Bone, 1999, 25:255-259. DOI: 10.1016/S8756-3282(99)00162-3
[14] Miheller P, Muzes G, Racz K, et al. Changes of OPG and RANKL concentrations in Crohn's disease after infliximab therapy[J]. Inflamm Bowel Dis, 2007, 13 : 1379-1384. DOI: 10.1002/ibd.20234
[15] Gong Y, Slee RB, Fukai N, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development[J]. Cell, 2001, 107:513-523. DOI: 10.1016/S0092-8674(01)00571-2
[16] Mizuguchi T, Furuta I, Watanabe Y, et al. LRP5, low- density-lipoprotein-receptor-related protein 5, is a determinant for bone mineral density[J]. J Hum Genet, 2004, 49:80-86. DOI: 10.1007/s10038-003-0111-6
[17] Todhunter CE, Sutherland-Craggs A, Bartram SA, et al. Influence of IL-6, COL1 Al, and VDR gene polymorphisms on bone mineral density in Crohn's disease[J]. Gut, 2005, 54:1579-1584. DOI: 10.1136/gut.2005.064212
[18] Asomaning K, Bertone-Johnson ER, Nasca PC, et al. The association between body mass index and osteoporosis in patients referred for a bone mineral density examination[J]. J Womens Health (Larchmt), 2006, 15 : 1028-1034. DOI: 10.1089/jwh.2006.15.1028
[19] 刘建彬, 高翔, 张芳宾, 等.炎症性肠病并发低骨量/骨质疏松的危险因素分析[J].中华内科杂志, 2009, 48: 833-836. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhnk200910013 [20] 张文燕, 袁耀宗.炎症性肠病患者骨代谢状况评估[J].中华消化杂志, 2009, 29:437-441. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhxhzz200907002 [21] Silvennoinen J, Lamberg-Allardt C, Karkkainen M, et al. Dietary calcium intake and its relation to bone mineral density in patients with inflammatory bowel disease[J]. J Intern Med, 1996, 240:285-292. DOI: 10.1046/j.1365-2796.1996.25862000.x
[22] Gilman J, Shanahan F, and Cashman KD. Determinants of vitamin D status in adult Crohn. disease patients, with particular emphasis on supplemental vitamin D use[J]. Eur J Clin Nutr, 2006, 60:889-896. DOI: 10.1038/sj.ejcn.1602395
[23] Cashman KD, Shanahan F. Is nutrition an aetiological factor for inflammatory bowel disease?[J]. Eur J Gastroenterol Hepatol, 2003, 15:607-613. DOI: 10.1097/00042737-200306000-00005
[24] 罗林枝, 徐苓.维生素K与骨质疏松[J].中国医学科学院学报, 2003, 25:346-349. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgyxkxyxb200303026 [25] Duggan P, O'Brien M, Kiely M, et al. Vitamin K status in patients with Crohn. disease and relationship to bone turnover[J]. Am J Gastroenterol, 2004, 99:2178-2185. DOI: 10.1111/j.1572-0241.2004.40071.x
[26] Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases[J]. Gastroenterology, 2003, 124:795-841. DOI: 10.1053/gast.2003.50106
[27] Scott EM, Gaywood I, Scott BB. Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease. British Society of Gastroenterology[J]. Gut, 2000, 46 Suppl 1 : il-8. https://www.ncbi.nlm.nih.gov/pubmed/10647595
[28] Palomba S, Manguso F, Orio F Jr, et al. Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study[J]. Menopause, 2008, 15 (4 Pt 1) :730-736. http://cn.bing.com/academic/profile?id=8d467942f11b3d678b9c40eb86bf48bf&encoded=0&v=paper_preview&mkt=zh-cn
[29] Chesnut CH 3rd, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis : the prevent recur- rence of osteoporotic fractures study. PROOF Study Group[J]. Am J Med, 2000, 109:267-276. DOI: 10.1016/S0002-9343(00)00490-3
[30] Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with different types of oral corticosteroids and effect of termination of corticosteroids on the risk of fractures[J]. Calcif Tissue Int, 2008, 82:249-257. DOI: 10.1007/s00223-008-9124-7
[31] Schoon EJ, Bollani S, Mills PR, et al. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease[J]. Clin Gastroenterol Hepatol, 2005, 3:113-121. DOI: 10.1016/S1542-3565(04)00662-7
[32] Reffitt DM, Meenan J, Sanderson JD, et al. Bone density improves with disease remission in patients with inflammatory bowel disease[J]. Eur J Gastroenterol Hepatol, 2003, 15 : 1267-1273. DOI: 10.1097/00042737-200312000-00003
[33] Franchimont N, Putzeys V, Collette J, et al. Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease[J]. Aliment Pharmacol Ther, 2004, 20: 607-614. DOI: 10.1111/j.1365-2036.2004.02152.x
[34] Abreu MT, Geller JL, Vasiliauskas EA, et al. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn. disease[J]. J Clin Gastroenterol, 2006, 40:55-63. DOI: 10.1097/01.mcg.0000190762.80615.d4
[35] Ryan BM, Russel MG, Schurgers L, et al. Effect of antitumour necrosis factor-alpha therapy on bone turnover in patients with active Crohn. disease : a prospective study[J]. Aliment Pharmacol Ther, 2004, 20:851-857. DOI: 10.1111/j.1365-2036.2004.02097.x
[36] Pazianas M, Rhim AD, Weinberg AM, et al. The effect of anti-TNF-alpha therapy on spinal bone mineral density in parents with Crohn's disease[J]. Ann NY Acad Sci, 2006, 1068:543-556. DOI: 10.1196/annals.1346.055
计量
- 文章访问数: 294
- HTML全文浏览量: 163
- PDF下载量: 50
下载:
